- Home
- NVAX vs MLKN Comparison
NVAX vs MLKN Comparison
Compare NVAX & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- MLKN
- Stock Information
- Founded
- NVAX 1987
- MLKN 1905
- Country
- NVAX United States
- MLKN United States
- Employees
- NVAX N/A
- MLKN N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- MLKN Office Equipment/Supplies/Services
- Sector
- NVAX Health Care
- MLKN Consumer Discretionary
- Exchange
- NVAX Nasdaq
- MLKN Nasdaq
- Market Cap
- NVAX 2.0B
- MLKN 1.7B
- IPO Year
- NVAX 1995
- MLKN N/A
- Fundamental
- Price
- NVAX $8.47
- MLKN $24.53
- Analyst Decision
- NVAX Buy
- MLKN
- Analyst Count
- NVAX 6
- MLKN 0
- Target Price
- NVAX $17.83
- MLKN N/A
- AVG Volume (30 Days)
- NVAX 5.8M
- MLKN 504.4K
- Earning Date
- NVAX 11-12-2024
- MLKN 12-18-2024
- Dividend Yield
- NVAX N/A
- MLKN 3.06%
- EPS Growth
- NVAX N/A
- MLKN 105.74
- EPS
- NVAX N/A
- MLKN 0.88
- Revenue
- NVAX $885,193,000.00
- MLKN $3,572,200,000.00
- Revenue This Year
- NVAX N/A
- MLKN $4.04
- Revenue Next Year
- NVAX N/A
- MLKN $4.16
- P/E Ratio
- NVAX N/A
- MLKN $27.81
- Revenue Growth
- NVAX N/A
- MLKN N/A
- 52 Week Low
- NVAX $3.53
- MLKN $22.35
- 52 Week High
- NVAX $23.86
- MLKN $31.73
- Technical
- Relative Strength Index (RSI)
- NVAX 41.69
- MLKN 54.98
- Support Level
- NVAX $6.81
- MLKN $23.25
- Resistance Level
- NVAX $10.39
- MLKN $24.43
- Average True Range (ATR)
- NVAX 0.66
- MLKN 0.60
- MACD
- NVAX 0.09
- MLKN 0.08
- Stochastic Oscillator
- NVAX 46.37
- MLKN 72.60
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract , International Contract & Specialty International & Specialty and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.